[The frontline of TMA management]

Area of Science:

• Hematology
• Pathology
• Pharmacology

Background:

• Thrombotic microangiopathy (TMA) encompasses severe conditions like thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic syndrome (HUS).
• TTP is distinguished by severe ADAMTS13 deficiency, arising from genetic mutations (congenital) or autoantibodies (acquired).
• Hemolytic-uremic syndrome (HUS) is often linked to complement pathway dysregulation, particularly in atypical forms (aHUS).

Purpose of the Study:

• To review the classification and current therapeutic strategies for thrombotic microangiopathy (TMA).
• To highlight advancements in treatments for both congenital and acquired TTP.
• To discuss the management of atypical hemolytic-uremic syndrome (aHUS).

Main Methods:

• Literature review of existing studies and guidelines on TMA.
• Analysis of approved and emerging therapeutic agents for TTP and aHUS.
• Examination of the etiological basis for TMA classification and targeted treatments.

Main Results:

• Recombinant ADAMTS13 presents a potential new treatment for congenital TTP.
• Caplacizumab is recommended for acquired TTP, alongside plasma exchange and rituximab.
• Eculizumab is an effective and well-tolerated treatment for aHUS.

Conclusions:

• TMA management is evolving with targeted therapies based on specific etiologies.
• Advances in understanding TMA pathophysiology have led to more effective treatment options.
• Personalized treatment approaches are crucial for improving outcomes in TMA patients.